StreetInsider.com News Articles

Form 4 CytoDyn Inc. For: Oct 20 Filed by: Hoffman Robert E.

Tue, 20 Oct 2026 20:29:00 -0400

si-local-file:///var/storage/secattach/20261020/27211604.html

Form DEFA14A CytoDyn Inc.

Mon, 19 Oct 2026 16:57:00 -0400

si-local-file:///var/storage/secattach/20261019/27204610.html

Form 8-K CytoDyn Inc. For: Oct 16

Mon, 19 Oct 2026 16:51:00 -0400

si-local-file:///var/storage/secattach/20261019/27204560.html

Form 10-Q CytoDyn Inc. For: Aug 31

Wed, 14 Oct 2026 08:34:00 -0400

si-local-file:///var/storage/secattach/20261014/27184362.html

Form EFFECT CytoDyn Inc.

Thu, 08 Oct 2026 06:04:00 -0400

si-local-file:///var/storage/secattach/20261008/27163118.html

Form 424B3 CytoDyn Inc.

Wed, 07 Oct 2026 17:03:00 -0400

http://archive.fast-edgar.com/20261007/A8L2M22CZ22CB252222222Z2MKGBKZ223282

Filed on: October 7, 2026

Form EFFECT CytoDyn Inc.

Mon, 05 Oct 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20261005/27145111.html

Form EFFECT CytoDyn Inc.

Mon, 05 Oct 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20261005/27145140.html

Form DEF 14A CytoDyn Inc. For: Sep 28

Mon, 28 Sep 2026 16:49:00 -0400

si-local-file:///var/storage/secattach/20260928/27115236.html

Form S-3 CytoDyn Inc.

Fri, 25 Sep 2026 17:08:00 -0400

http://archive.fast-edgar.com/20260925/A8LHB22CZ22CK242222M22Z2G8M2ZZ223282

Filed on: September 25, 2026

Form POS AM CytoDyn Inc.

Fri, 25 Sep 2026 16:58:00 -0400

si-local-file:///var/storage/secattach/20260925/27108074.html

Form POS AM CytoDyn Inc.

Fri, 25 Sep 2026 16:56:00 -0400

si-local-file:///var/storage/secattach/20260925/27108064.html

Natera partners with CytoDyn for colorectal cancer drug development

Thu, 04 Jun 2026 08:01:32 -0400

Natera Inc. (NASDAQ: NTRA) and CytoDyn Inc. (OTCQB: CYDY) announced a strategic collaboration to evaluate circulating tumor DNA dynamics and generate molecular insights for CytoDyn's metastatic colorectal cancer development program.

Under the agreement, Natera will assess clinical trial samples from CytoDyn's CLOVER Phase 2 study using its Signatera assay for molecular residual disease detection. The study evaluates leronlimab in combination with trifluridine/tipiracil and bevacizumab in patients with previously treated metastatic colorectal cancer.

Natera will provide customized real-world data analyses using its oncology database, which contains more than 2 million plasma timepoints with clinical and imaging records. The company will integrate molecular response

Natera partners with CytoDyn for colorectal cancer drug development

Thu, 04 Jun 2026 08:01:32 -0400

Natera partners with CytoDyn for colorectal cancer drug development

Thu, 04 Jun 2026 08:01:32 -0400

Natera partners with CytoDyn for colorectal cancer drug development

Thu, 04 Jun 2026 08:01:32 -0400

Natera and CytoDyn Announce Strategic Collaboration to Advance ctDNA-Guided Development and Molecular Response Analysis in Metastatic Colorectal Cancer